NCT02183870已完成2 期
EUCROSS: A Phase II Trial to Evaluate Efficacy and Safety of Crizotinib Treatment in Advanced Adenocarcinoma of the Lung Harbouring ROS1 Translocations
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 18
- 主要终点
- Objective Response Rate (ORR); evaluation criteria: investigator assessed RECIST v.1.1 analysis
研究概览
简要总结
EUCROSS is a phase II trial to evaluate the efficacy and safety of crizotinib in patients with adenocarcinoma of the lung harbouring ROS1 translocations. Patients will be treated with 250mg crizotinib bid until progression or intolerable toxicity.
详细描述
EUCROSS is a phase II trial to evaluate the efficacy and safety of crizotinib in patients with adenocarcinoma of the lung harbouring ROS1 translocations. In individual treatment attempts and an ongoing phase I trial crizotinib has shown remarkable effects on this selected subgroup of lung cancer patients. Crizotinib is a tyrosine kinase inhibitor, blocking the catalytic activity of rearranged ALK and ROS1 as well as MET. The patients eligible for the trial will be treated with 250mg crizotinib twice-daily. Tumor response to treatment will be assessed every 6 weeks by CT or MRI scans. In case of progression treatment beyond may be conducted if clinically indicated. To identify mechanisms of resistance to crizotinib treatment, an optional re-biopsy may be performed in these cases and fresh frozen tumor material will analyzed at the University of Cologne.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with adenocarcinoma of the lung that is locally advanced or metastatic independent from the number of prior lines of therapy, i.e. including non-pretreated patients (UICC stage IIIB or IV)
- •Positive for ROS1 translocation by central FISH-testing
- •Ability to swallow pills
- •Age > 18 years
- •ECOG performance status 0 to 2
- •Life expectancy of at least 12 weeks
- •Disease measurable per Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1)
- •Any prior treatment (chemotherapy, radiation or surgery) must have been completed at least 2 weeks prior to initiation of study medication
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 14 days prior to screening:
- •Hemoglobin ≥ 8.0 g/dL
- •Absolute neutrophil count (ANC) ≥ 1,000 /mm3
- •Platelet count ≥ 50 000/µL
- •Total bilirubin ≤ 2 x upper limit of normal (ULN)
- •Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (AP) ≤ 2,5 x ULN or ≤ 5 x ULN in case of liver involvement
- •PT-INR/PTT ≤ 1.5 x ULN
- •Serum creatinine ≤ 2 times ULN
- •Calculated creatinine clearance (CLcr) ≥ 40 ml/min (Cockcroft-Gault formula)
- •Written informed consent
- •Negative serum pregnancy test within 3 days prior to start of dosing premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for ≥ 1 year.
- •Fertile men and women must have an effective method of contraception during treatment and for at least 3 months after completion of treatment as directed by their physician. Effective methods of contraception result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices). At the discretion of the investigator, acceptable methods of contraception may include total abstinence where lifestyle of the patient ensures compliance (Periodic abstinence and withdrawal are not acceptable methods of contraception).
排除标准
- •Previous treatment with specific ALK or ROS1 inhibitors
- •Current treatment within another therapeutic clinical trial
- •Other history of ongoing malignancy that would potentially interfere with the interpretation of efficacy (early stage or chronic disease is allowed if not requiring active therapy or intervention and being under control)
- •Pregnancy or breastfeeding
- •Use of drugs or foods that are known potent CYP3A4 inhibitors, including but not limited to atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole and grapefruit or grapefruit juice
- •Use of drugs that are known potent CYP3A4 inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John's wort
- •Use of drugs that are CYP3A4 substrates with narrow therapeutic indices, including but not limited to dihydroergotamine, ergotamine, pimozide, astemizole, cisapride, and terfenadine
- •Active CNS metastases. Patients with brain metastasis are eligible if asymptomatic for ≥ 14 days before starting study medication and off corticosteroids.
- •History of or known carcinomatous meningitis or leptomeningeal disease
- •Known diagnosis of HIV, active hepatitis B and/or C (testing is not mandatory)
- •Any person being in an institution on assignment of the respective authority against his/her own will
- •Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information
- •Ongoing cardiac dysrhythmias of CTCAE grade ≥2, uncontrolled atrial fibrillation of any grade or QTcF interval > 470ms
- •Patients with known interstitial fibrosis or interstitial lung disease
- •Any of the following within 3 months prior to first crizotinib administration:
- •Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack
研究组 & 干预措施
Crizotinib
Experimental
Patients are treated in this single-arm trial with oral crizotinib 250 mg b.i.d.. Treatment dose will be adjusted according to the protocol if indicated. Treatment will be conducted until disease progression or beyond disease progression according to the protocol if clinically indicated.
干预措施: Crizotinib (Drug)
结局指标
主要结局
Objective Response Rate (ORR); evaluation criteria: investigator assessed RECIST v.1.1 analysis
时间窗: From time of beginning of treatment until the documention of response according to RECIST v1.1 (expected average 12 months) .
CT/MRI scans will be performed to evaluate the efficacy of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 fusion genes (primary outcome measure: objective response rate (ORR) according to RECIST v.1.1)
次要结局
- Duration of Response (DR); evaluation criteria: investigator assessed RECIST v.1.1 analysis(From time of beginning of treatment until the documention of progression according to RECIST v1.1 (expected average 12 months).)
- Patient Reported Outcomes (PRO) (EORTC QLQ-C30, EORTC QLQ-LC13)(Questionnaires (EORTC QLQ-LC13, EORTC QLQ-C30) completed at baseline and every 4 weeks from beginning of treatment until end of study.)
- Objective Response Rate (ORR), Overall Survival (OS), Progression Free Survival (PFS), Duration of Response (DR), Time to Tumor Response, Disease Control Rate (DCR); evaluation criteria: RECIST v1.1 by independent radiologic review(From time of beginning of treatment until the documention of response according to RECIST v1.1 (expected average 12 months) .)
- Progression Free Survival (PFS) according to RECIST v1.1; evaluation criteria: investigator assessed RECIST v.1.1 analysis(From time of beginning of treatment until the first documented event of progression according to RECIST v1.1 (expected average 12 months).)
- Overall Survival (OS); evaluation criteria: investigator assessed RECIST v.1.1 analysis(From beginning to end of study (Last subject last visit (LSLV)) (up to approximately 24 months).)
- Time to Tumor Response; evaluation criteria: investigator assessed RECIST v.1.1 analysis(From time of beginning of treatment until the first documented event of response according to RECIST v1.1 (expected average 3 months).)
- Disease Control Rate (DCR); evaluation criteria: investigator assessed RECIST v.1.1 analysis(From beginning of treatment to week 6, 12 and 24 according to RECIST v1.1 (expected average 3 months).)
- Safety/Adverse Events and tolerability in all patients treated with crizotinib assessed by number and severity of adverse events as recorded on the case report form, vital signs, laboratory variables, physical examination, electrocardiogram and RECIST1.1(From beginning of treatment until 28 days post treatment (expected average 12 months).)
- To evaluate the efficacy of crizotinib treatment in the patient subgroup with ROS1 translocation confirmed by the CAGE technology regarding the objective response rate (ORR) (evaluation criteria: investigator assessed RECIST v1.1)(From time of beginning of treatment until the documention of response according to RECIST v1.1 (expected average 12 months) .)
研究者
Prof. Dr. Juergen Wolf
Professor Dr. med., Leader of the LCGC
University of Cologne
研究点 (18)
Loading locations...
相似试验
已完成
2 期
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1Hematologic CancersSolid TumorsMetastatic CancerNCT02034981UNICANCER246
已完成
2 期
Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung CancerLung Cancer, Nonsmall CellNCT03088930University of Colorado, Denver3
终止
2 期
S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After CrizotinibAdenocarcinoma of the LungLarge Cell Lung CancerRecurrent Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNCT02134912SWOG Cancer Research Network1
已完成
2 期
Study of Crizotinib for ROS1 and MET Activated Lung CancerNon-squamous Non-small-cell Lung CancerStage IV Non-small Cell Lung CancerROS1 Gene RearrangementMET Activating MutationMET AmplificationNCT04084717University Health Network, Toronto33
招募中
不适用
Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung CancerNon-small Cell Lung CancerNCT03647111Hunan Province Tumor Hospital120